logo

Stock Screener

Forex Screener

Crypto Screener

ATRC

AtriCure, Inc. (ATRC)

$

32.2

-0.57 (-1.77%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

0.0040

Market cap

Market cap

1.6 Billion

Price to sales ratio

Price to sales ratio

3.3792

Debt to equity

Debt to equity

0.1703

Current ratio

Current ratio

4.1078

Income quality

Income quality

-0.6039

Average inventory

Average inventory

75.1 Million

ROE

ROE

-0.0829



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, which are single-use disposable radio frequency products. It also provides multifunctional pens and linear ablation devices, such as the MAX Pen device that allows surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, stimulation, and ablate cardiac tissue with the same instrument. Additionally, the Coolrail device is designed for creating longer linear ablation lines. The cryoICE Cryoablation System enables users to perform linear ablations of varying lengths, while the EPi-Sense Guided Coagulation System serves as a single-use disposable device for addressing symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure's product lineup includes the AtriClip System, an implantable device used with a single-use disposable applier, and the LARIAT System, which provides a suture-based solution for soft-tissue closure that accommodates diverse anatomical shapes. The company also markets Lumitip Dissectors for tissue separation, Glidepath guides for clamp placement, Subtle Cannulas to enhance access for EPi-Sense catheters, and various reusable cardiac surgery instruments utilized in procedures for heart valve repair or replacement. The gross profit stands at $347,524,000.00 highlighting the company's profitability from core operations. The cost of revenue for the company is $117,783,000.00 showcasing its production and operational expenses. The company reported depreciation and amortization expenses of $18,733,000.00 reflecting the wear and tear of its assets. Furthermore, the company incurred an interest expense of $6,407,000.00 signifying its debt servicing obligations, and the operating expenses total $387,537,000.00 encompassing various operational costs incurred. In terms of market positioning, the stock is affordable at $32.20 making it an attractive option for budget-conscious investors. With an average trading volume of 567,455.00 the stock indicates moderate liquidity, providing a balanced trading experience for investors. The company has a market capitalization of $1,594,057,780.00 which classifies it as a small-cap player. AtriCure is a key player in the Medical - Instruments & Supplies industry, contributing significantly to the overall market landscape and belonging to the Healthcare sector, thereby driving innovation and growth within its field.

What is AtriCure, Inc. (ATRC)'s current stock price?

The current stock price of AtriCure, Inc. (ATRC) is $32.20 as of 2025-07-01. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in AtriCure, Inc. (ATRC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.

Analysts predict AtriCure, Inc. stock to fluctuate between $20.20 (low) and $43.11 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-07-01, AtriCure, Inc.'s market cap is $1,594,057,780, based on 49,504,900 outstanding shares.

Compared to Eli Lilly & Co., AtriCure, Inc. has a Lower Market-Cap, indicating a difference in performance.

To buy AtriCure, Inc. (ATRC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ATRC. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.

Revenue: $465,307,000 | EPS: -$0.95 | Growth: 43.94%.

Visit https://www.atricure.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $89.18 (2021-11-05) | All-time low: $18.94 (2024-06-18).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

ATRC

businesswire.com

a month ago

AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may acc.

ATRC

zacks.com

2 months ago

Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?

The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ATRC

seekingalpha.com

2 months ago

AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript

AtriCure, Inc. (NASDAQ:ATRC ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Matthew O'Brien - Piper Sandler Companies John McAulay - Stifel Financial Corp. Lily Lozada - JPMorgan Chase & Co. Marie Thibault - BTIG, LLC Danny Stauder - Citizens JMP Securities, LLC Mike Matson - Needham & Company, LLC Danielle Antalffy - UBS Group AG Suraj Kalia - Oppenheimer & Co. Inc. Operator Good afternoon, and welcome to AtriCure's First Quarter 2025 Earnings Conference Call. This call is being recorded for replay purposes.

ATRC

zacks.com

2 months ago

AtriCure (ATRC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ATRC

zacks.com

2 months ago

AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

AtriCure (ATRC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.

ATRC

businesswire.com

2 months ago

AtriCure Reports First Quarter 2025 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2025 financial results. “Our performance in the first quarter reflects outstanding execution of several new product launches and the strength of our overall business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “As.

ATRC

businesswire.com

3 months ago

AtriCure to Announce First Quarter 2025 Financial Results

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2025 financial results on Tuesday, April 29, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, April 29, 2025, to discuss its first quarter 2025 financial results. Those interested in list.

ATRC

businesswire.com

4 months ago

AtriCure to Host Analyst & Investor Day on March 26, 2025

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa.

ATRC

zacks.com

5 months ago

AtriCure (ATRC) Upgraded to Buy: Here's What You Should Know

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

ATRC

seekingalpha.com

5 months ago

AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript

AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener